All updated as on -
With a projected 7.1% CAGR between 2023 and 2030, the global autism spectrum disorder treatment market is projected to rise from its 2022 valuation of $2.08 billion. Market expansion is expected to be aided by the discovery and development of new medicines for the treatment of individuals with autism spectrum disorder (ASD). The second-generation medicines Vraylar (cariprazine) and Rexulti (brexpiprazole) are being studied by AbbVie Inc. and Otsuka Pharmaceutical Co., Ltd. in patients with autism, as reported in a July 2022 article. The approvals that follow the completion of clinical trials are expected to boost the expansion of the market.
During the early phases of the unusual epidemic, a lot of healthcare-related businesses had to close, which in turn slowed down production. Children with autism have had their therapy sessions cancelled or put on hold due to the closing of therapy centres and other services connected to autism spectrum disorders. However, strong adoption of telehealth systems by the patient's caregivers/family was spurred by the rising anxiety levels in autistic patients and the possibility of contracting Covid-19 since these patients fell under vulnerable groups. In addition, this drove up interest in therapies and off-label uses for pharmaceuticals like SSRIs, antipsychotics, and sleep aids. During COVID-19, the market expanded in part due to more people turning to the internet to purchase autism drugs.
The market is anticipated to be driven by organisations conducting extensive research studies to examine the safety and efficacy of medications in individuals with ASD. The promising findings of these investigations provide fresh avenues for business expansion. Stalicla, for example, finished phase 1b trials of precision medicine candidate STP1 for individuals with autism spectrum disorder in March 2022. As a result, the market is expected to be propelled by the trial's conclusion and following product approvals.
Despite the growing demand for reliable clinical studies and viable treatments for autism spectrum disorder (ASD), no medications have yet been licenced for this condition. Some of the primary problems that slow down research and drug development are knowledge gaps and complicated models in clinical translation research. Despite numerous efforts during the era of focused treatment, no drug has been shown to be both safe and effective in treating the underlying symptoms of ASD. Thus, the potential for the market to be stunted by the absence of licenced medications to treat people with ASD.
One of the main drivers of the global market for ASD treatments is the increasing public awareness of the illness and the significance of early diagnosis. The public's and medical community's awareness of ASD has risen dramatically in recent years, facilitating both its diagnosis and understanding. More people are asking for diagnostic screenings and starting early interventions for ASD now that they know more about the condition. Diagnosing and treating ASD early is crucial because it allows for immediate support and intervention. Early interventions, such as behavioural therapies, have been shown to improve children with ASD's language, social, and coping skills. The market for autism spectrum disorder diagnostic services is growing rapidly to meet the rising demand. More people are learning about ASD, which has led to the development of initiatives and screening programmes. Public health campaigns, educational activities, and the participation of advocacy groups have all contributed to improved awareness of ASD among parents, carers, and medical professionals, which has led to higher rates of discovery and treatment.
Report Coverage
Global Autism Spectrum Disorder Treatment research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Autism Spectrum Disorder Treatment report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Autism Spectrum Disorder Treatment competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Autism Spectrum Disorder Treatment market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Autism Spectrum Disorder Treatment market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Autism Spectrum Disorder Treatment market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Curemark LLC; Bristol-Myers Squibb Company; Merck & Co., Inc.; Novartis AG.; Eli Lilly and Company; Pfizer Inc.; Johnson & Johnson Services Inc.; Otsuka Pharmaceutical Co., Ltd.; Yamo Pharmaceuticals; F. Hoffman-La Roche Ltd.; Axial Therapeutics Inc.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Autism Spectrum Disorder Treatment market based on the below-mentioned segments:
Global Autism Spectrum Disorder Treatment Market, By Type
Antipsychotic Drugs
Selective Serotonin Reuptake Inhibitors
Stimulants
Sleep Medications
Others
Global Autism Spectrum Disorder Treatment market, By Application
Autistic Disorder
Asperger Syndrome
Pervasive Developmental Disorder
Others
Global Autism Spectrum Disorder Treatment Market, By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Autism Spectrum Disorder Treatment market, Regional Analysis
During the early phases of the unusual epidemic, a lot of healthcare-related businesses had to close, which in turn slowed down production. Children with autism have had their therapy sessions cancelled or put on hold due to the closing of therapy centres and other services connected to autism spectrum disorders. However, strong adoption of telehealth systems by the patient's caregivers/family was spurred by the rising anxiety levels in autistic patients and the possibility of contracting Covid-19 since these patients fell under vulnerable groups. In addition, this drove up interest in therapies and off-label uses for pharmaceuticals like SSRIs, antipsychotics, and sleep aids. During COVID-19, the market expanded in part due to more people turning to the internet to purchase autism drugs.
The market is anticipated to be driven by organisations conducting extensive research studies to examine the safety and efficacy of medications in individuals with ASD. The promising findings of these investigations provide fresh avenues for business expansion. Stalicla, for example, finished phase 1b trials of precision medicine candidate STP1 for individuals with autism spectrum disorder in March 2022. As a result, the market is expected to be propelled by the trial's conclusion and following product approvals.
Despite the growing demand for reliable clinical studies and viable treatments for autism spectrum disorder (ASD), no medications have yet been licenced for this condition. Some of the primary problems that slow down research and drug development are knowledge gaps and complicated models in clinical translation research. Despite numerous efforts during the era of focused treatment, no drug has been shown to be both safe and effective in treating the underlying symptoms of ASD. Thus, the potential for the market to be stunted by the absence of licenced medications to treat people with ASD.
One of the main drivers of the global market for ASD treatments is the increasing public awareness of the illness and the significance of early diagnosis. The public's and medical community's awareness of ASD has risen dramatically in recent years, facilitating both its diagnosis and understanding. More people are asking for diagnostic screenings and starting early interventions for ASD now that they know more about the condition. Diagnosing and treating ASD early is crucial because it allows for immediate support and intervention. Early interventions, such as behavioural therapies, have been shown to improve children with ASD's language, social, and coping skills. The market for autism spectrum disorder diagnostic services is growing rapidly to meet the rising demand. More people are learning about ASD, which has led to the development of initiatives and screening programmes. Public health campaigns, educational activities, and the participation of advocacy groups have all contributed to improved awareness of ASD among parents, carers, and medical professionals, which has led to higher rates of discovery and treatment.
Report Coverage
Global Autism Spectrum Disorder Treatment research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Autism Spectrum Disorder Treatment report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Autism Spectrum Disorder Treatment competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Autism Spectrum Disorder Treatment market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Curemark LLC; Bristol-Myers Squibb Company; Merck & Co., Inc.; Novartis AG.; Eli Lilly and Company; Pfizer Inc.; Johnson & Johnson Services Inc.; Otsuka Pharmaceutical Co., Ltd.; Yamo Pharmaceuticals; F. Hoffman-La Roche Ltd.; Axial Therapeutics Inc. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Autism Spectrum Disorder Treatment Market from 2021 to 2030.
- Market Forecast for Autism Spectrum Disorder Treatment Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Autism Spectrum Disorder Treatment competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Autism Spectrum Disorder Treatment
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Autism Spectrum Disorder Treatment market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Autism Spectrum Disorder Treatment market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Curemark LLC; Bristol-Myers Squibb Company; Merck & Co., Inc.; Novartis AG.; Eli Lilly and Company; Pfizer Inc.; Johnson & Johnson Services Inc.; Otsuka Pharmaceutical Co., Ltd.; Yamo Pharmaceuticals; F. Hoffman-La Roche Ltd.; Axial Therapeutics Inc.
Primary Target Market
- Market Players of Autism Spectrum Disorder Treatment
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Autism Spectrum Disorder Treatment market based on the below-mentioned segments:
Global Autism Spectrum Disorder Treatment Market, By Type
Antipsychotic Drugs
Selective Serotonin Reuptake Inhibitors
Stimulants
Sleep Medications
Others
Global Autism Spectrum Disorder Treatment market, By Application
Autistic Disorder
Asperger Syndrome
Pervasive Developmental Disorder
Others
Global Autism Spectrum Disorder Treatment Market, By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Autism Spectrum Disorder Treatment market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive autism spectrum disorder treatment market market research and competitor analysis for your business to help you develop more profound insights into the autism spectrum disorder treatment market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the autism spectrum disorder treatment market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.